Abstract
Deficiency of very-long-chain acyl-CoA dehydrogenase (VLCAD) is the most common long-chain fatty acid oxidation defect and presents with heterogeneous clinical manifestations. Accumulation of long-chain acylcarnitines and deficiency of free carnitine have often been proposed to play an important role in disease pathogenesis. The VLCAD-deficient mouse exhibits similar clinical and biochemical phenotypes to those observed in humans and, therefore, represents an excellent model to study VLCAD deficiency. We measured carnitine and acylcarnitine profiles in liver, skeletal muscle (SkM), bile, and blood from VLCAD knock-out mice and controls under nonstressed and various stress conditions. Carnitine and acylcarnitines were extracted from body fluids with methanol and from tissues with acetonitrile, respectively, and were analyzed as their butyl esters using electrospray ionization tandem mass spectrometry. Fasting combined with a cold challenge for 8 h significantly induced liver long-chain acylcarnitine and free carnitine production. Acylcarnitines in SkM predominantly accumulated during exercise with a concomitant decrease of free carnitine. Changes in blood free carnitine did not correlate with carnitine homeostasis in liver and SkM. Our results demonstrate different tissue-specific long-chain acylcarnitine profiles in response to various stressors, which may be of importance with respect to the heterogeneous clinical manifestations of VLCAD deficiency in humans. Furthermore, we conclude that carnitine biosynthesis in the liver seems sufficiently active to maintain liver carnitine levels during increased demand. Our data suggest that carnitine supplementation in long-chain β-oxidation defects may not be required, and blood carnitine concentrations do not reflect tissue carnitine homeostasis.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- HZ:
-
heterozygous
- KO:
-
knock-out
- SkM:
-
skeletal muscle
- VLCAD:
-
very-long-chain acyl-CoA dehydrogenase
- VLCADD:
-
very-long-chain acyl-CoA dehydrogenase deficiency
- WT:
-
wild-type
References
Spiekerkoetter U, Sun B, Zytkovicz T, Wanders R, Strauss AW, Wendel U 2003 MS/MS-based newborn and family screening detects asymptomatic patients with very long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 143: 335–342
Gregersen N, Andresen BS, Corydon MJ, Corydon TJ, Olsen R, Bolund L, Bross P 2001 Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat 18: 169–189
Cox GF, Souri M, Aoyama T, Rockenmacher S, Varvogli L, Rohr F, Hashimoto T, Korson MS 1998 Reversal of severe hypertrophic cardiomyopathy and an excellent neurophysiologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 133: 247–253
Brown-Harrison MC, Nada MA, Sprecher H, Vianey-Saban C, Farquhar J Jr, Gilladoga AC, Roe CR 1996 Very-long-chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem Mol Med 58: 59–65
Spiekerkoetter U, Tokunaga C, Wendel U, Mayatepek E, Duran M, Wijburg FA, Wanders RJ, Strauss AW 2004 Changes in blood carnitine and acylcarnitine profiles of very long-chain acyl-CoA dehydrogenase-deficient mice subjected to stress. Eur J Clin Invest 34: 191–196
Touma EH, Rashed MS, Vianey-Saban C, Sakr A, Divry P, Gregersen N, Andresen BS 2001 A severe genotype with favourable outcome in very long chain acyl-CoA dehydrogenase deficiency. Arch Dis Child 84: 58–60
Spiekerkotter U, Schwahn B, Korall H, Trefz FK, Andresen BS, Wendel U 2000 Very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency: monitoring of treatment by carnitine/acylcarnitine analysis in blood spots. Acta Paediatr 89: 492–495
Pauly DF, Pepine CJ 2003 The role of carnitine in myocardial dysfunction. Am J Kidney Dis 41: S35–S43
Tein I 2002 Role of carnitine and fatty acid oxidation and its effects in infantile epilepsy. J Child Neurol 17: 57–82
Bonnet D, Martin D, de Lonlay P, Villain E, Jouvet P, Rabier D, Brivet M, Saudubray JM 1999 Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 100: 2248–2253
Exil VJ, Roberts R, Sims H, McLaughlin JE, Malkin RA, Gardner CD, Ni G, Rottman JN, Strauss AW 2003 Very-long-chain acyl-coenzyme A dehydrogenase deficiency in mice. Circ Res 93: 448–455
Cox KB, Hamm DA, Millington DS, Matern D, Vockley J, Rinaldo P, Pinkert CA, Rhead WJ, Lindsey JR, Wood PA 2001 Gestational, pathologic and biochemical differences between very-long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse. Hum Mol Genet 10: 2069–2077
Giak Sim K, Carpenter K, Hammond J, Christodoulou J, Wilcken B 2002 Quantitative fibroblast acylcarnitine profiles in mitochondrial fatty acid β-oxidation defects: phenotype/metabolite correlations. Mol Genet Metab 76: 327–334
Papaioannou VE, Johnson RS 1993 Gene Targeting: A Practical Approach. Oxford University Press, Oxford, pp 107–146
Vreken P, van Lint AE, Bootsma AH, Overmars H, Wanders RJ, van Gennip AH 1999 Quantitative plasma acylcarnitine analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidemias and fatty acid oxidation defects. J Inherit Metab Dis 22: 302–306
Chace DH, DiPerna JC, Mitchell BL, Sgroi B, Hofman LF, Naylor EW 2001 Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem 47: 1166–1182
van Vlies N, Tain L, Overmars H, Bootsma AH, Kulik W, Wanders RJA, Wood PA, Vaz FM 2004 Characterization of carnitine and fatty acid metabolism in the long-chain acyl-CoA dehydrogenase deficient mouse. Biochem J epub ahead of print
Sandor A, Cseko J, Kispal G, Alkonyi I 1990 Surplus acylcarnitines in the plasma of starved rats derive from the liver. J Biol Chem 265: 22313–22316
Ogilvie I, Pourfazam M, Jackson S, Stockdale C, Bartlett K, Turnbull DM 1994 Very long-chain acyl coenzyme A dehydrogenase deficiency presenting with exercise-induced myoglobinuria. Neurology 44: 467–473
Scholte HR, Van Coster RN, de Jonge PC, Poorthuis BJ, Jeneson JA, Andresen BS, Gregersen N, de Klerk JB, Busch HF 1999 Myopathy in very-long-chain acyl-CoA dehydrogenase deficiency: clinical and biochemical differences with the fatal cardiac phenotype. Neuromuscul Disord 9: 313–319
Krajcovicova-Kudlackova M, Simoncic R, Bederova A, Babinska K, Beder I 2000 Correlation of carnitine levels to methionine and lysine intake. Physiol Res 49: 399–402
Tanphaichitr V, Broquist HP 1974 Site of carnitine biosynthesis in the rat. J Nutr 104: 1669–1673
Cox RA, Hoppel CL 1974 Carnitine and trimethylaminobutyrate synthesis in rat tissues. Biochem J 142: 699–701
Haigler HT, Broquist HP 1974 Carnitine synthesis in rat tissues slices. Biochem Biophys Res Commun 56: 676–681
Vaz FM, Wanders RJ 2002 Carnitine biosynthesis in mammals. Biochem J 361: 417–429
Rashed MS, Ozand PT, Bennett MJ, Barnard JJ, Govindaraju DR, Rinaldo P 1995 Inborn errors of metabolism diagnosed in sudden death cases by acylcarnitine analysis of postmortem bile. Clin Chem 41: 1109–1114
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spiekerkoetter, U., Tokunaga, C., Wendel, U. et al. Tissue Carnitine Homeostasis in Very-Long-Chain Acyl-CoA Dehydrogenase–Deficient Mice. Pediatr Res 57, 760–764 (2005). https://doi.org/10.1203/01.PDR.0000157915.26049.47
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/01.PDR.0000157915.26049.47
This article is cited by
-
Renal response to short- and long-term exercise in very-long-chain acyl-CoA dehydrogenase-deficient (VLCAD−/−) mice
Molecular and Cellular Pediatrics (2014)
-
Experimental evidence for protein oxidative damage and altered antioxidant defense in patients with medium‐chain acyl‐CoA dehydrogenase deficiency
Journal of Inherited Metabolic Disease (2014)
-
Long-term Correction of Very Long-chain Acyl-CoA Dehydrogenase Deficiency in Mice Using AAV9 Gene Therapy
Molecular Therapy (2012)
-
Current issues regarding treatment of mitochondrial fatty acid oxidation disorders
Journal of Inherited Metabolic Disease (2010)
-
Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models
Journal of Inherited Metabolic Disease (2010)
